Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation

We conducted a phase I-II study of transplantation conditioning with clofarabine-melphalan-alemtuzumab for patients with advanced hematologic malignancies. Ten patients were accrued to the phase I portion, which utilized an accelerated titration design. No dose-limiting toxicity was observed, and cl...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: van Besien, Koen, Stock, Wendy, Rich, Elizabeth, Odenike, Olatoyosi, Godley, Lucy A., O’Donnell, Peter H., Kline, Justin, Nguyen, Vu, del Cerro, Paula, Larson, Richard A., Artz, Andrew S.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3423318/
https://ncbi.nlm.nih.gov/pubmed/22079470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2011.10.041
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires